RxDoctor Payments Data

Andrew Park, MD

Urology · Mansfield, OHNPI 1730610718

Payments from drug & device makers

$994in general payments, 2019–2025

Across 17 payments — averaging $58.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$665
  • Calyxo, Inc.$73
  • AbbVie$65
  • Sumitomo Pharma America, Inc.$59
  • Accord Healthcare, Inc.$33
  • Merck$32
  • plus $65 from 3 others

What the payments were for

  • Travel & lodging$46247%
  • Food & beverage$49850%
  • Gifts$333%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$994 in reported general payments places this provider in the 30th percentile of 485 urology providers in Ohio.

See all urology providers in Ohio

Medicare billing

Part B allowed, 2024
$109,623
Medicare patients
275
Services billed
8,883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron133$76,819
GemtesaVibegron13$12,948
Tamsulosin Hcl397$4,950
Solifenacin Succinate55$3,192
Testosterone Cypionate73$2,557
Finasteride96$1,116
Oxybutynin Chloride ErOxybutynin Chloride69$851
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip35$615
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim100$355
Ampicillin Trihydrate29$321
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$198
Ciprofloxacin Hcl59$189
Cephalexin33$127
Ketorolac Tromethamine11$106
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen18$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$59$12,94813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 485 urology providers in Ohio.

Other urology in Mansfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →